Funding Opportunities

NIH Funding Opportunities

Notice of Extension of the Response Date for NOT-AR-15-007 "Request for Information (RFI) on the Future Directions of Lupus Research"
Notice NOT-AR-15-009 from the NIH Guide for Grants and Contracts
Tue, 20 Jan 2015 12:49:23 EST

Innovations in Measuring and Managing Addiction Treatment Quality Challenge Prize Competition
Notice NOT-DA-15-040 from the NIH Guide for Grants and Contracts
Wed, 21 Jan 2015 08:50:31 EST

Notice of Correction to NOT-GM-14-135 "Notice of Change in Application Due Dates for PAR-13-280 'Support of NIGMS Program Project Grants (P01)'"
Notice NOT-GM-15-015 from the NIH Guide for Grants and Contracts
Wed, 21 Jan 2015 08:41:52 EST

Salary Limitation on FY 2015 AHRQ Grants, Cooperative Agreements, and Contracts
Notice NOT-HS-15-003 from the NIH Guide for Grants and Contracts
Wed, 21 Jan 2015 09:46:24 EST

Reminder to AHRQ Grantees that FY2010 Funds will Expire on September 30, 2015
Notice NOT-HS-15-004 from the NIH Guide for Grants and Contracts
Thu, 22 Jan 2015 09:12:33 EST

Notice of Intent to Publish a Funding Opportunity Announcement for Regional Medical Libraries for the National Network of Libraries of Medicine (UG4)
Notice NOT-LM-15-003 from the NIH Guide for Grants and Contracts
Thu, 22 Jan 2015 09:00:28 EST

Request for Information (RFI): Improving Mental Health Outcomes in Alaska Native Communities Rapidly, Substantially, and Sustainably
Notice NOT-MH-15-007 from the NIH Guide for Grants and Contracts
Wed, 21 Jan 2015 09:00:43 EST

Notice of the Extension of the Expiration Date for PAR-12-152 "NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01)"
Notice NOT-NS-15-011 from the NIH Guide for Grants and Contracts
Wed, 21 Jan 2015 09:12:56 EST

Notice of the Extension of the Expiration Date for PAR-12-163 "NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22)"
Notice NOT-NS-15-012 from the NIH Guide for Grants and Contracts
Wed, 21 Jan 2015 09:03:25 EST

Reminders Related to the NIH/AHRQ Policy for Application Submission
Notice NOT-OD-15-059 from the NIH Guide for Grants and Contracts
Thu, 22 Jan 2015 09:08:52 EST

Findings of Research Misconduct
Notice NOT-OD-15-060 from the NIH Guide for Grants and Contracts
Thu, 22 Jan 2015 09:15:54 EST

Population Dynamics Centers Research Infrastructure FY 2015 (P2C)
Funding Opportunity RFA-HD-15-009 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research productivity, develop junior scientists, and maximize the efficiency of research support.
Fri, 23 Jan 2015 10:09:01 EST

Medical Rehabilitation Research Resource (P2C)
Funding Opportunity RFA-HD-15-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications from institutions/organizations that propose to build research infrastructure to promote external collaboration with the medical rehabilitation community. The aim of this FOA is to create a national network of research cores that provide access to collateral expertise in biomedical, behavioral, engineering, and/or psychosocial fields that is particularly relevant to medical rehabilitation research. We are particularly interested in supporting infrastructure programs in clinical trial design, engineering and the environment, individualized medical rehabilitation and dynamic reassessment, and applied behavioral supports for rehabilitation research and healthy outcomes. However, other areas of expertise may be proposed provided they offer unique research opportunities and have potential for promoting medical rehabilitation research and improving outcomes for people with disabilities. In response to this FOA, applicants should propose a program of research resources and collaborative opportunities in a specific research domain. This may be accomplished through a workshops, written material, and websites, consultations, collaborations, and pilot funding. In addition, the research core may support activities within the grantee institution related to technique development, adaptation, and validation. To accomplish the aims of the FOA, applicants may propose collaborations to other institutional sites, provided that they cover the appropriate administrative and logistical issues.
Fri, 23 Jan 2015 02:17:02 EST

Metabolomics Core for the Undiagnosed Diseases Network (UDN) (U01)
Funding Opportunity RFA-RM-15-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to establish a Metabolomics Core to augment clinical and laboratory findings of the Undiagnosed Diseases Network (UDN) and to assist the Network in the diagnosis of patients with undiagnosed diseases. Responsive applications will describe a plan to provide comprehensive analytical methods, analyses, technologies, and metabolomics expertise to the UDN to aid in clinical diagnosis and investigate potential mechanisms underlying phenotypic changes in patients. Due to the rare, even unique, disorders of UDN patients, the application should describe the need to develop specialized, "boutique" assays and methods of measurement in analyses of both normal and abnormal compounds of the diseased metabolome.
Wed, 21 Jan 2015 10:55:30 EST

Prevention Research in Mid-Life Adults (R21)
Funding Opportunity PA-15-097 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years.
Thu, 22 Jan 2015 09:53:25 EST

Prevention Research in Mid-Life Adults (R01)
Funding Opportunity PA-15-098 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years.
Thu, 22 Jan 2015 10:05:30 EST

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33)
Funding Opportunity PA-15-099 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for Phased Innovation (R21/R33) projects to determine whether reductions in illicit drug use are associated with positive changes in health-related and other functional outcomes in individuals with substance use disorders (SUDs). Functional outcomes include, for example, reductions in morbidity, mortality, criminal justice involvement, overall healthcare expenditures. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by possible transition to expanded research support (R33 phase). The transition to the R33 phase will be determined by NIH program evaluation of successful achievement of the milestones set for the R21 phase. The ultimate goal of this FOA is to provide evidence that will enable regulatory authorities to accept reductions in illicit drug use as a valid outcome measure in clinical trials of pharmacotherapies for the treatment of SUDs.
Fri, 23 Jan 2015 01:49:29 EST

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH2/UH3)
Funding Opportunity PAR-15-095 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. The UH2 phase of this FOA supports analytical validation of assays for these markers that must be achieved within two years before an assay may undergo clinical validation. The UH3 phase of this FOA supports the clinical validation of established assays for up to three years using specimens from retrospective or prospective studies from NCI-supported or other clinical trials. In both the UH2 and UH3 phases, clinical laboratory staff, technical and other needs must be an integral part of the application. Assays proposed for this FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials. Investigators responding to this FOA must address both UH2 and UH3 phases.
Wed, 21 Jan 2015 08:48:15 EST

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH3)
Funding Opportunity PAR-15-096 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants to this FOA must have an assay whose performance has been analytically validated within specimens similar to those for the intended clinical use of the assay and marker. The UH3 mechanism supports the clinical validation of established assays for up to three years using specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Assays proposed for this FOA may be used to validate existing assays for use in other trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. Clinical laboratory staff, technical and other needs must be an integral part of the application. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.
Wed, 21 Jan 2015 08:52:05 EST